Muraoka's questions to SHIONOGI & CO (SGIOY) leadership • Q1 2022
Question
Muraoka from Morgan Stanley sought clarity on the S-217622 approval process in China, asking if it depends on Japanese approval and if there are government stockpiling plans. He also inquired about capital allocation priorities, including M&A and shareholder returns, if profit targets are met.
Answer
John Keller, SVP of R&D, explained that China's review speed depends on a classification by local authorities, making both independent and dependent approval paths possible. On capital allocation, Keller noted potential M&A opportunities, while Ryuichi Kiyama, Senior Executive Officer, reiterated a focus on strategic investments for the 2030 vision and a commitment to shareholder returns.